|
Video: What is a Stock Split?
|
|
Turning Point Therapeutics is a clinical-stage biopharmaceutical company designing and developing therapies that target genetic drivers of cancer. Co.'s main drug candidate, repotrectinib, is being evaluated for the treatment of patients with ROS1+ advanced non-small-cell lung cancer and patients with NTRK+ advanced solid tumors. Elzovantinib, Co.'s MET/SRC/CSF1R inhibitor, is being evaluated in its ongoing Phase 1 SHIELD-1 clinical trial, in patients with advanced solid tumors harboring genetic alterations in MET. Co.'s clinical trial of its RET inhibitor, TPX-0046 in patients with advanced solid tumors is ongoing. Co.'s fourth drug candidate, TPX-0131, is an ALK inhibitor. According to our TPTX stock split history records, TPTX has had 1 split. | |
|
TPTX (TPTX) has 1 split in our TPTX stock split history database. The split for TPTX took place on October 04, 2006. This was a 1 for 10 reverse split, meaning for each 10 shares of TPTX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 100 share position following the split.
When a company such as TPTX conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the TPTX stock split history from start to finish, an original position size of 1000 shares would have turned into 100 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into TPTX shares, starting with a $10,000 purchase of TPTX, presented on a split-history-adjusted basis factoring in the complete TPTX stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/18/2019 |
|
End date: |
09/07/2022 |
|
Start price/share: |
$26.67 |
|
End price/share: |
$76.01 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
185.00% |
|
Average Annual Total Return: |
36.18% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$28,502.50 |
|
Years: |
3.39 |
|
|
|
Date |
Ratio |
10/04/2006 | 1 for 10 |
|
|